Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates

• Published in: Haematologica (Roma) Vol. 107; no. 2; pp. 519 - 531
• Main Authors: Slingsby, Martina H Lundberg, Vijey, Prakrith, Tsai, I-Ting, Roweth, Harvey, Couldwell, Genevieve, Wilkie, Adrian R, Gaus, Hans, Goolsby, Jazana M, Okazaki, Ross, Terkovich, Brooke E, Semple, John W, Thon, Jonathan N, Henry, Scott P, Narayanan, Padmakumar, Italiano, Jr, Joseph E
• Format: Journal Article
• Language: English
• Published: Italy Fondazione Ferrata Storti 01.02.2022; Ferrata Storti Foundation
• Subjects: Blood Platelets; Clinical Medicine; Hematologi; Hematology; Humans; Klinisk medicin; Leukocytes; Medical and Health Sciences; Medicin och hälsovetenskap; Oligonucleotides, Antisense - genetics; Oligonucleotides, Antisense - pharmacology; Oligonucleotides, Antisense - therapeutic use; Platelet Activation; Platelet Count

Antisense oligonucleotides (ASO) are DNA-based, disease-modifying drugs. Clinical trials with 2'-O-methoxyethyl (2'MOE) ASO have shown dose- and sequence-specific lowering of platelet counts according to two phenotypes. Phenotype 1 is a moderate (but not clinically severe) drop in platelet...